Below is the final program.
Click here for a preliminary meeting program.
Wednesday Oct 28 | Thursday Oct 29 | Friday Oct 30 | Saturday Oct 31
WEDNESDAY, OCTOBER 28
Registration opens at 6:30pm
7:00pm – 9:00pm
WELCOME RECEPTION
THURSDAY, OCTOBER 29
Registration opens at 7:00am
8:00am – 8:30am
Keynote Address: Mechanisms of Bone Metastasis
Gregory R. Mundy, M.D.
Vanderbilt Center for Bone Biology, Nashville, TN
8:30am – 10:00am
Cancer Stem Cells
Regulation of Cancer Stem Cells by Stem Cell Niche
Laura Calvi, M.D.
University of Rochester School of Medicine, Rochester, NY
Cancer Stem Cells in Multiple Myeloma
William Matsui, M.D.
Johns Hopkins University, Baltimore, MD
*The role of fibronectin in the bone marrow metastatic niches
Inaam Nakchbandi, M.D., FACP
University of Heidelberg and Max-Planck Institute of Biochemistry, Heidelberg, Germany
*●Aldehyde dehydrogenase is a putative marker for prostate cancer stem cells with tumor- and bone metastasis- initiating ability
Cristel van den Hoogen, M.Sc.
Leiden University Medical Center, Leiden, Netherlands
10:00am – 10:30am Break & Exhibits
10:30am – 12:00pm
EFFECTS OF HEMATOPOIETIC CELLS AND CANCER
Solid Tumors Target the Hematopoietic Stem Cell Niche for Metastasis
Russell Taichman, D.M.D., D.M.Sc.
University of Michigan School of Dentistry, Ann Arbor, MI
Immune Microenvironment in Myeloma
Madhav Dhodapkar, M.D.
Yale University, New Haven, CT
*●The Inhibitory Effects of Megakaryocytes in Prostate Cancer Skeletal Metastasis
Xin Li, Ph.D.
University of Michigan School of Dentistry, Ann Arbor, MI
*Zoledronic acid-induced IPP/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with Vgamma9Vdelta2 T cell-mediated cancer cell death in vitro and in vivo
Ismahene Benzaid, Graduate Student
INSERM, Lyon, France
12:00pm – 2:00pm Lunch & Poster Session
2:00pm – 3:30pm
CANCER ASSOCIATED FIBROBLASTS
Interactive Biology in Stromal Responses: A Driving Force in Carcinogenesis
Simon Hayward, Ph.D.
Vanderbilt University Medical Center, Nashville, TN
Co-evolution of Reactive Stroma and Cancer Progression
David R. Rowley, Ph.D.
Baylor College of Medicine, Houston, TX
The Bone Marrow Microenvironment in Multiple Myeloma
Claire Edwards, Ph.D.
Vanderbilt Center for Bone Biology, Nashville, TN
3:30pm – 4:00pm Break & Exhibits
4:00pm – 6:00pm
TUMOR ANGIOGENESIS
Myeloma Cells-Osteoclast Interactions Promote Angiogenesis
Toshio Matsumoto, M.D.
University of Tokushima, Tokushima, Japan
*T cells and myeloid-derived suppressor cells in breast cancer bone metastases: regulation of osteoclastogenesis and immunosuppression
Pierrick J. Fournier, Ph.D.
University of Virginia, Charlottesville, VA (at time of abstract submission)
*The EphB4/ephrinB2 signaling; a potential targeted therapy for myeloma bone disease
Shmuel Yaccoby, Ph.D.
University of Arkansas for Medical Sciences, Little Rock, AR
IMAGING AND PROTEOMICS OF BONE METASTASIS
New Approaches to Imaging Bone Metastasis
Gabri van der Pluijm, M.D.
Leiden University Medical Center, Leiden, Netherlands
*Predicting Sites of Metastasis: Molecular Imaging of the Pre-Metastatic Niche
Monica Shokeen, Ph.D.
Washington University School of Medicine, Saint Louis, MO
*Evaluation of treatment response of breast cancer bone metastases to an αvβ3 integrin antagonist using DCE-MRI and VCT
Tobias Baeuerle, M.D.
German Cancer Research Center, Heidelberg, Germany
THURSDAY, OCTOBER 29 (con't)
7:00pm – 8:30pm
Satellite Evening Sesion
Open to all attendees.
Novel Strategies for Bone-Directed Therapy Across the Cancer Continuum
Welcome & Introduction
Allan Lipton, M.D.
Milton S. Hershey Medical Center, Hershey, PA
Presentation 1:
Current Approaches and Research Directions with RANKL Inhibitors in Optimizing Bone Health in Breast Cancer
Robert Coleman, MBBS, M.D., FRCP
University of Sheffield, Sheffield, United Kingdom
Presentation 2:
Prostate Cancer: Beyond Bisphosphonates— Evolving Evidence Supporting RANKL Inhibitors
Matthew Smith, M.D., Ph.D.
Massachusetts General Hospital, Boston, MA
Presentation 3:
Mitigating Bone Complications in Multiple Myeloma: What’s Current and What’s on the Horizon?
G. David Roodman, M.D., Ph.D.
University of Pittsburgh Medical Center, Pittsburgh, PA
Audience Q&A - All Faculty
This session is supported through an educational donation from Amgen.
FRIDAY, OCTOBER 30
8:00am – 9:30am
BIOLOGY AND TREATMENT OF PROSTATE CANCER BONE METASTASIS
Clinical Approaches to Patients with Prostate Cancer and Bone Metastasis
Kenneth J. Pienta, M.D.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
The Detection, Isolation and Characterization of Disseminated Prostate Cancer Cells from Bone Marrow: Implications for Clinical Management and Insight into Tumor Dormancy
Robert L. Vessella, Ph.D.
University of Washington School of Medicine, Seattle, WA
Molecular Mechanisms of Bone Metastasis in Prostate Cancer
Gregory A. Clines, M.D.
University of Virginia Cancer Center, Charlottesville, VA
9:30am – 10:00am Break & Exhibits
10:00am – 12:00pm
TGF-B AND METASTASIS
Novel Genes that Mediate Tumor-Stromal Interactions in Osteolytic Bone Metastasis
Yibin Kang, Ph.D.
Princeton University, Princeton, NJ
*●Involvement of the SLIT2/ROBO1 Pathway in Breast Cancer Bone Metastasis
Vincent Gonin, Graduate Student
INSERM, Lyon, France
*●Oncolytic adenovirus targeting TGF-ß signaling: Acontinued: A Novel gene therapy approach for the treatment of bone metastasis
Zebin Hu, Ph.D.
Northshore Research Institute, University of Chicago, Evanston, IL
*Sympathetic outflow to bone primes and fuels the osteolytic vicious cycle via osteoblasts
J. Preston Campbell, Graduate Student
Vanderbilt Center for Bone Biology, Nashville, TN
*Differential roles for host derived proteases in the tumorbone microenvironment
Conor Lynch, Ph.D.
Vanderbilt University, Nashville, TN
PREVENTION OF BONE METASTASIS
Are Bisphosphonates Anti-Cancer Drugs?
Robert Coleman, MBBS, M.D., FRCP
University of Sheffield, Sheffield, United Kingdom
12:00pm – 2:00pm Lunch & Poster Session
2:00pm – 3:30pm
MATHEMATICAL MODELING AND DOSE DENSE CHEMOTHERAPY
Mathematical Modeling and Carcinogenesis
Larry Norton, M.D.
Memorial Sloan-Kettering Cancer Center, New York, NY
Microenvironmental Independence in Tumor Progression: An Integrated Approach
Alexander R.A. Anderson, Ph.D.
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
*Bone marrow microenvironment up-regulates Pim-2 expression in myeloma cells to enhance myeloma cell survival
Masahiro Abe, M.D., Ph.D.
University of Tokushima Graduate School of Medicine, Tokushima, Japan
*RANKL inhibition plus Tamoxifen blocks ER+ breast tumor growth in bone metastases and prevents tumor-induced bone loss in a new mouse model
Jude Canon, Ph.D.
Amgen, Inc., Thousand Oaks, CA
3:30pm – 4:00pm Break & Exhibits
4:00pm – 5:30pm
NEW ANTI-RESORPTIVE AGENTS
Efficacy of New Anti-Resorptives for Bone Metastasis
Allan Lipton, M.D.
Milton S. Hershey Medical Center, Hershey, PA
Bone Turnover Markers (BTM) in Metastatic Bone Diseases
Patrick Garnero, Ph.D., D.Sc.
INSERM, Lyon, France
FRIDAY, OCTOBER 30
*Saracatinib (AZD0530) inhibits bone resorption in healthy volunteers and cancer patients
Richard D. Finkelman, D.D.S., Ph.D.
AstraZeneca, Wilmington, DE
*AZD2171 inhibits the development and progression of bone and brain metastasis in a mouse metastasis model
Juan Juan Ivy Yin, M.D., Ph.D.
National Cancer Institute (NCI), Bethesda, MD
7:00pm – 8:30pm
SATELLITE EVENING SESSION
Open to all attendees.
Optimizing Bone Health in Patients with Multiple Myeloma
Introduction/Chair
G. David Roodman, M.D., Ph.D.
University of Pittsburgh Medical Center, Pittsburgh, PA
Presentation 1:
Molecular and Clinical Rationale for the Use of Bisphosphonates in Multiple Myeloma
G. David Roodman, M.D., Ph.D.
Presentation 2:
Molecular Pathways and Bone Markers
John D. Shaughnessy, Jr., Ph.D.
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Presentation 3:
Restoring Bone Homeostasis in Multiple Myeloma: Novel Therapies and Combinations
Noopur Raje, M.D.
Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
Best Practices: A Panel Discussion
Chair and Faculty
Participant Q&A Session
This activity is jointly sponsored by the University of Cincinnati, Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.
SATURDAY, OCTOBER 31
8:00am – 9:00am
PREVENTION OF BONE METASTASIS
Potential Mechanisms of Bisphosphonates as Anti-Cancer Drugs
Michael Rogers, Ph.D.
University of Aberdeen, Aberdeen, Scotland
Interferon Gamma for Prevention of Bone Metastasis
Katherine Weilbaecher, M.D.
Washington University School of Medicine, St. Louis, MO
9:00am – 11:00am
ANABOLIC AGENTS FOR OSTEOLYTIC DISEASE
Sclerostin as an Anabolic Agent for Bone Metastasis
Clemens W.G.M. Lowik, M.D.
Leiden University Medical Center, Leiden, Netherlands
Targeting DKK1 in Myeloma
John D. Shaughnessy, Jr., Ph.D.
Myeloma Institute for Research and Therapy, Little Rock, AR
*ACE-011, a Soluble Activin Type IIA Receptor IgG-Fc Fusion Protein, Significantly Increases Bone Mineral
Niels Borgstein, M.D.
Acceleron Pharma, Cambridge, MA
*EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix
Ji Zhu, Ph.D.
University of Pennsylvania, Philadelphia, PA
CLOSING REMARKS
* Oral presentation selected from submitted abstracts
● Abstract selected for Young Investigator Award